An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
about
Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patientsProtective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies.Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
P2860
An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@ast
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@en
type
label
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@ast
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@en
prefLabel
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@ast
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@en
P2093
P2860
P1433
P1476
An optimized IFN-γ ELISpot ass ...... lls of cell-mediated immunity.
@en
P2093
Anne Rascle
Benedikt Asbach
Charlotte Tonar
Hanna Bendfeldt
Julia Batzilla
Ludwig Deml
Ralf Wagner
Richard Kiener
Sascha Barabas
Tamara Lugner
P2860
P2888
P356
10.1186/S12865-017-0195-Y
P577
2017-03-07T00:00:00Z
P6179
1084250118